Kathleen Tregoning - Sanofi President
| SNYN Stock | MXN 816.01 23.99 2.86% |
President
Ms. Kathleen Tregoning has served as Executive Vice President External Affairs, Member of the Executive Committee of Sanofi S.A. since February 2017 since 2017.
| Age | 47 |
| Tenure | 7 years |
| Phone | 33 1 53 77 40 00 |
| Web | https://www.sanofi.com |
Sanofi Management Efficiency
The company has return on total asset (ROA) of 0.0607 % which means that it generated a profit of $0.0607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0959 %, meaning that it generated $0.0959 on every $100 dollars invested by stockholders. Sanofi's management efficiency ratios could be used to measure how well Sanofi manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Sang Lee | Samsung Electronics Co | 56 | |
| Troy Richardson | DXC Technology | N/A | |
| Craig Stanley | McEwen Mining | 44 | |
| Neil Manna | DXC Technology | 54 | |
| Dan Hushon | DXC Technology | N/A | |
| Joanne Mason | DXC Technology | 49 | |
| Sun Yoon | Samsung Electronics Co | 59 | |
| Jong Yoon | Samsung Electronics Co | 54 | |
| Gary Stockman | DXC Technology | N/A | |
| Dong Jeon | Samsung Electronics Co | 57 | |
| Sang Kim | Samsung Electronics Co | 57 | |
| Tae Jung | Samsung Electronics Co | 52 | |
| Paul Saleh | DXC Technology | 60 | |
| Franz Lazarus | Costco Wholesale | 71 | |
| Yeong Gil | Samsung Electronics Co | 57 | |
| Gi Kim | Samsung Electronics Co | 58 | |
| Juan Arriaga | Southern Copper | 55 | |
| Du Yoon | Samsung Electronics Co | 54 | |
| Tong Wang | Samsung Electronics Co | 54 | |
| Andrew Iaboni | McEwen Mining | 41 | |
| Raul Ruisanchez | Southern Copper | 65 | |
Management Performance
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 |
Sanofi Leadership Team
Elected by the shareholders, the Sanofi's board of directors comprises two types of representatives: Sanofi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi's management team and ensure that shareholders' interests are well served. Sanofi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee | ||
| Emmanuel Babeau, Independent Director | ||
| Roy Papatheodorou, Gen VP | ||
| Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team | ||
| Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee | ||
| Dieter Weinand, Executive Vice President Member of the Executive Board | ||
| Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team | ||
| Eva SchaeferJansen, Head Relations | ||
| Fabienne Lecorvaisier, Director | ||
| George Grofik, Vice President of Investor Relations | ||
| Karen Linehan, Member of the Executive Board, Member of the Management Board, Senior Vice President General Counsel | ||
| Klaus Pohle, Independent Director | ||
| John Reed, President - Global Research & Development, Member of the Executive Committee | ||
| Bernard Charles, Independent Director | ||
| Melanie Lee, Independent Director | ||
| Pierre Chancel, Sr Marketing | ||
| Christophe Babule, Director | ||
| Bonnie Bassler, Director | ||
| Thomas Suedhof, Independent Director | ||
| Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee | ||
| Laurent Attal, Director | ||
| JeanRene Fourtou, Independent Director | ||
| JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
| Josephine Fubara, Chief Care | ||
| Christian Mulliez, Director | ||
| Robert Castaigne, Independent Director | ||
| Laurent Gilhodes, Principal Accounting | ||
| Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team | ||
| Uwe Bicker, Independent Director | ||
| Josep Catlla, Head Communications | ||
| Claudie Haignere, Independent Director | ||
| Olivier Brandicourt, CEO, Director and Member of Strategy Committee | ||
| Paul Hudson, CEO Director | ||
| Bruno Mnard, Chief officer | ||
| Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team | ||
| Dante Beccaria, Global VP | ||
| Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee | ||
| William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee | ||
| Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team | ||
| David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe | ||
| Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team | ||
| Diane Souza, Independent Director | ||
| Carole Piwnica, Independent Director | ||
| Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team | ||
| Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee | ||
| Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team | ||
| Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team | ||
| DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee | ||
| Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team | ||
| Igor Landau, Director | ||
| Patrick Kron, Independent Director | ||
| Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee | ||
| Gerard Kemmel, Independent Director | ||
| SuetFern Lee, Independent Director | ||
| Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team | ||
| David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team | ||
| Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee | ||
| Suet Lee, Independent Director |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 2.69 T | |||
| Shares Outstanding | 2.47 B | |||
| Shares Owned By Institutions | 10.26 % | |||
| Price To Earning | 414.95 X | |||
| Price To Book | 1.61 X | |||
| Price To Sales | 52.71 X |
Currently Active Assets on Macroaxis
| LAAC | Lithium Americas Corp | |
| F | Ford Motor | |
| CHPT | ChargePoint Holdings | |
| AXL | American Axle Manufacturing | |
| ICLN | iShares Global Clean |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Sanofi Stock analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |